Semaglutide Added to Research Exemption Peptides Portfolio

We are pleased to add to the portfolio of research exemption peptides, joining other GLP-1 (glucagon like peptide) agonists, our latest offering Semaglutide, which exhibits many unique characteristics that make it a compelling tool for diabetes management.

For the full brochure of all the research exemption peptides available, please click here for the brochure.